AK002
Phase 2Small molecule
AK002 is one of 97 small molecule programs targeting Allergic Conjunctivitis. It is currently in Phase 2.
4
Indications
9
Total Trials
0
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Daliresp
AstraZenecaPhase 3
Fludara
SanofiPhase 3
Nereus
VVanda Pharmaceuticals
Phase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
AK002
AAllakos Inc.
Phase 2
Prograf
VVeloxis Pharmaceuticals
Preclinical
IDP-124 Lotion
BBausch Health Americas, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Eosinophilic Gastritis3 trials
Tics2 trials
Allergic Conjunctivitis1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AK002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAllakos Inc.